Mariana Grieben | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Mariana Grieben | Cancer Cell Biology | Best Researcher Award

University of Lübeck | Germany

Dr. Mariana Grieben is a biochemist and structural biologist whose research spans the molecular mechanisms of membrane proteins and virus-host interactions. She earned her Ph.D. in structural biology with a focus on ATP synthases and subsequently advanced her expertise as a postdoctoral researcher at the Structural Genomics Consortium (SGC), University of Oxford, where she investigated the structural characterization of human integral membrane proteins, including TRP channels, TMEM proteins, and SLCs, in collaboration with pharmaceutical companies to identify therapeutic small molecules. She later contributed to pandemic-related research at STRUBI, Oxford, elucidating the roles of SARS-CoV-2 non-structural membrane proteins 3, 4, and 6. Currently, she is a Group Leader at the Institute of Biochemistry, University of Lübeck, where she also pursues a teaching qualification. Her research contributions include the cryo-EM and X-ray structures of TRPP1, TRPC6, TRPA1, and TMEM45A, alongside work on viral proteins such as CHPV M protein and hHAX-1, advancing understanding of diseases including polycystic kidney disease, focal segmental glomerulosclerosis, cancer, pain, and virus-induced heart failure. Dr. Grieben has published 7 peer-reviewed journal articles, holds an h-index of 3 with 3 citations, and has completed 7 major research projects. She is an active member of GBM and maintains collaborations with academia and industry.

Profile: Scopus

Featured Publications:

Wang, Q., Corey, R. A., Hedger, G., Aryal, P., Grieben, M., Nasrallah, C., Baronina, A., Pike, A. C. W., Shi, J., Carpenter, E. P., & Sansom, M. S. P. (2020). Lipid interactions of a ciliary membrane TRP channel: Simulation and structural studies of polycystin-2. Structure, 28(2), 169-184.e5.

 

 

Evgeny Deforzh | Cancer | Best Researcher Award

Published on by Cell Biologist

Dr. Evgeny Deforzh | Cancer | Best Researcher Award

Brigham and Women’s Hospital, Harvard University | United States

Dr. Evgeny Deforzh is a molecular biologist whose work focuses on the regulation of RNA, microRNAs, chromatin dynamics, and their roles in cancer and neurological disease. After earning his B.S. and M.S. in Biology from Saint Petersburg State University and a Ph.D. in Molecular Biology from Paris‑Saclay University, he completed postdoctoral research as a Research Fellow and subsequently served as Instructor in Neurology at Brigham & Women’s Hospital. His peer‑reviewed contributions include insights into how WEE1 regulators switch roles in cell cycle control, protection of cyclin mRNAs from translational repression, the impact of glioblastoma‑derived extracellular vesicles on astrocyte transformation, and the nuclear modulation of splicing by oncogenic microRNAs. More recently, his work has elucidated promoter/enhancer RNA regulation of super‑enhancers, and miRNA pathways as therapeutic targets in gliomas and meningiomas. To date, Dr. Deforzh has published ~15–20 independent original research articles (first‑, co‑first, or senior‑author) with many additional co‐authored papers. His publications have been cited in the literature ~800‑1,200 times, giving him an approximate h‑index of 12–15. His research has advanced understanding of RNA regulatory networks in cancer and offers potential translational pathways for diagnostics and therapy.

Profiles: Google Scholar | Scopus

Featured Publications:

Zeng, A., Wei, Z., Rabinovsky, R., Jun, H. J., El Fatimy, R., Deforzh, E., & Arora, R. (2020). Glioblastoma-derived extracellular vesicles facilitate transformation of astrocytes via reprogramming oncogenic metabolism. iScience, 23(8), 101420.

Deforzh, E., Uhlmann, E. J., Das, E., Galitsyna, A., Arora, R., Saravanan, H., … (2022). Promoter and enhancer RNAs regulate chromatin reorganization and activation of miR-10b/HOXD locus, and neoplastic transformation in glioma. Molecular Cell, 82(10), 1894–1908.e5.

El Fatimy, R., Zhang, Y., Deforzh, E., Ramadas, M., Saravanan, H., Wei, Z., … (2022). A nuclear function for an oncogenic microRNA as a modulator of snRNA and splicing. Molecular Cancer, 21(1), 17.

Poller, W., Sahoo, S., Hajjar, R., Landmesser, U., & Krichevsky, A. M. (2023). Exploration of the noncoding genome for human-specific therapeutic targets—Recent insights at molecular and cellular level. Cells, 12(22), 2660.

Deforzh, E., Vargas, T. R., Kropp, J., Vandamme, M., Pinna, G., & Polesskaya, A. (2016). IMP-3 protects the mRNAs of cyclins D1 and D3 from GW182/AGO2-dependent translational repression. International Journal of Oncology, 49(6), 2578–2588.

Kratassiouk, G., Pritchard, L. L., Cuvellier, S., Vislovukh, A., Meng, Q., … (2016). The WEE1 regulators CPEB1 and miR-15b switch from inhibitor to activators at G2/M. Cell Cycle, 15(5), 667–677.

Alexander Tsankov | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Assoc. Prof. Dr. Alexander Tsankov | Cancer Cell Biology | Best Researcher Award

Icahn School Of Medicine At Mount Sinai | United States

Alexander Tsankov is a leading researcher in computational biology and cancer genomics, known for his contributions to single-cell and spatial transcriptomics. He holds dual bachelor’s degrees in Plan II Honors and Electrical and Computer Engineering from the University of Texas at Austin, and earned his M.S. and Ph.D. in Electrical Engineering and Computer Science from MIT. His research focuses on understanding the cellular and molecular mechanisms underlying cancer progression and tissue remodeling, with an emphasis on glioblastoma, lung adenocarcinoma, and colorectal cancer. Dr. Tsankov has published extensively in top-tier journals such as Nature, Nature Communications, Cancer Discovery, Nature Genetics, and Immunity. He has authored over 50 peer-reviewed publications, with an h-index of 36 and more than 15,000 citations according to Google Scholar. His work has earned him several prestigious honors, including the NIH NRSA postdoctoral fellowship and the NSF graduate fellowship. Dr. Tsankov frequently serves as a senior or corresponding author, highlighting his leadership in the field of computational oncology and single-cell genomics.

Profile: Google Scholar

Featured Publications:

  • “Learning the cellular origins across cancers using single-cell chromatin landscapes”

  • “Cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinoma”

  • “Single cell profiling of human airway identifies tuft-ionocyte progenitor cells displaying cytokine-dependent differentiation bias in vitro”

  • “Single-cell dissection of the genotype-immunophenotype relationship in glioblastoma”

  • “Glioblastoma shift from bulk to infiltrative growth is guided by plexin-B2-mediated microglia alignment in invasive niches”

  • “Oncofetal reprogramming drives phenotypic plasticity in WNT-dependent colorectal cancer”

  • “NOTCH1 drives sexually dimorphic immune responses in hepatocellular carcinoma”

  • “Microglia and monocyte-derived macrophages drive progression of pediatric high-grade gliomas and are transcriptionally shaped by histone mutations”

  • “Single cell view of tumor microenvironment gradients in pleural mesothelioma”

  • “Hypoxia drives shared and distinct transcriptomic changes in two invasive glioma stem cell lines”

Yavuz Tekelioğlu | Cancer Cell Biology | Best Academic Researcher Award

Published on by Cell Biologist

Prof. Dr. Yavuz Tekelioğlu | Cancer Cell Biology | Best Academic Researcher Award

Prof. Dr. Yavuz Tekelioğlu | Karadeniz Technical University | Turkey

Prof. Dr. Yavuz Tekelioğlu is a distinguished professor at Karadeniz Technical University’s Faculty of Medicine, specializing in histology, embryology, and toxicology. He has built a prolific academic career focused on cellular and tissue analysis using advanced methods like flow cytometry. Since beginning as a research assistant, he has steadily advanced through academic ranks, culminating in a full professorship. He has supervised numerous theses, contributing significantly to training future scientists. His research emphasizes the protective effects of antioxidants and stem cell therapies on tissue toxicity, with over 100 peer-reviewed publications. Active in professional societies, he also provides comprehensive educational instruction in medicine and dentistry. Prof. Tekelioğlu is committed to advancing biomedical research, particularly in reproductive and hepatic toxicology, through innovative experimental approaches.

Publication Profile:

Scopus

Education:

Prof. Dr. Yavuz Tekelioğlu completed his higher education at Karadeniz Technical University, where he earned his PhD after serving as a research assistant. His academic foundation is firmly rooted in medical sciences, with a focus on histology and embryology. During his doctoral studies, he developed expertise in experimental toxicology and cellular biology, particularly utilizing flow cytometry for immunophenotyping. His training includes specialized certifications in scientific research ethics, flow cytometry techniques, and institutional educational management. These credentials equip him to conduct rigorous, ethical research and provide effective academic leadership. Continuous participation in national and international workshops and symposiums reflects his commitment to staying current with cutting-edge methodologies and ethical standards in biomedical research.

Experience:

Starting as a research assistant, Prof. Tekelioğlu quickly advanced to PhD research assistant, assistant professor, associate professor, and finally full professor at Karadeniz Technical University. Over more than three decades, he has taught histology and embryology to medical, dental, and graduate students while supervising numerous theses on tissue toxicity and protective agents. He has led multiple TÜBİTAK and university-funded projects focusing on mesenchymal stem cells and toxicological evaluations using flow cytometry and histopathology. His academic service extends to practical flow cytometry training, contributing to capacity building in biomedical research. His administrative roles include coordinating research ethics training and educational management. He is a member of prominent scientific societies, contributing to Turkey’s scientific community. His career demonstrates dedication to both research and education.

Research Focus:

Prof. Dr. Tekelioğlu’s research primarily focuses on the histopathological and immunological effects of toxic agents on reproductive and hepatic tissues. His work extensively explores the protective roles of antioxidants like vitamin E, lycopene, beta-glucan, and Coenzyme Q10 against methotrexate-induced toxicity. Employing flow cytometry, histology, and biochemical assays, his studies provide mechanistic insights into cellular apoptosis, oxidative stress, and tissue regeneration. He investigates mesenchymal stem cells for their therapeutic potential in tissue repair and immunomodulation. His experimental models often include rats and mice, enabling controlled studies of drug-induced organ damage and protective interventions. By bridging toxicology with cellular analysis, his research contributes to safer clinical drug use and novel treatment strategies. Additionally, his recent work on ovarian and cardiac protection highlights translational relevance. His interdisciplinary approach combines toxicology, reproductive biology, and flow cytometry, establishing him as a leader in biomedical research.

Publication Top Notes: 

  • Coenzyme Q10 may protect ovarian tissue against methotrexate-induced gonadotoxicity: a biochemical, flow cytometric, and histopathological study

  • A Comparison of the Flow Cytometric Analysis Results of Benign and Malignant Serous Tumors of the Ovary

  • Should combined MTX and CoQ10 use be reconsidered in terms of steatosis? A biochemical, flow cytometry, histopathological experimental study

  • Histological and flow cytometric evaluation of astaxanthin’s effects against cyclophosphamide induced heart injury in rats

  •  Melamine exposure during the weaning period negatively affects ovarian reserve

Conclusion:

Prof. Dr. Yavuz Tekelioğlu is well-qualified and highly suitable for the Best Academic Researcher Award based on his extensive career, strong research leadership, significant scholarly contributions, and educational impact. His focused expertise on toxicology, histology, and cellular analysis is both relevant and impactful.

With strategic enhancements in international collaborations and visibility, he can further solidify his standing as a leading academic researcher. Nonetheless, his current achievements and dedication clearly merit recognition at this level.

Vaclav Ranc | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Assoc. Prof. Dr. Vaclav Ranc | Cancer Cell Biology | Best Researcher Award

Assoc. Prof. Dr. Vaclav Ranc | Palacký University in Olomouc | Czech Republic

Dr. Václav Ranc is a distinguished analytical chemist and data analyst with over 15 years of experience in academia and applied research. Based in the Czech Republic, he leads a research group at Palacký University Olomouc, specializing in nanotechnology, plasmonic and electronic nanosensors, and advanced analytical techniques. He holds a Ph.D. in Analytical Chemistry and a Habilitation in Physical Chemistry. Dr. Ranc has published over 80 peer-reviewed scientific articles and holds several international patents. He has secured and managed significant EU funding, including Horizon Europe and MSCA projects, showcasing his excellence in both research and project leadership. His expertise spans Raman spectroscopy, mass spectrometry, and LC/GC methods, coupled with data analysis in Python, Matlab, and R. He is a regular presenter at international conferences and a recognized innovator in the fields of biosensing and nanomaterials.

Publication Profiles: 

Google Scholar
Orcid
Scopus

Education:

Dr. Václav Ranc earned his MSc. in Analytical Chemistry from Palacký University Olomouc (UPOL) in 2005, where he focused on the discrimination of enantiomers using mass spectrometry techniques such as LC-MS and CE-MS. He continued at UPOL to complete his Ph.D. in Analytical Chemistry, specializing in chiral analysis with HPLC-MS and GC-MS. His academic trajectory culminated in a Habilitation in Physical Chemistry, reflecting his advancements in Raman microscopy, SERS, and mass spectrometry. Dr. Ranc’s education is deeply rooted in analytical and physical chemistry, with a significant emphasis on developing and applying sophisticated separation and detection techniques for complex biological and clinical samples. His academic background is further enriched by international research experiences in Sweden and Switzerland, where he worked on electroanalytical techniques and nanoLC-MS applications for neurotransmitter analysis.

Experience:

Dr. Václav Ranc currently serves as the Head of a Research Group at Palacký University Olomouc, managing a 20-member team focused on cutting-edge nanomaterials and analytical chemistry. He has led the group’s scientific, financial, and personnel management, improving research output by 30%. Previously, he worked as a Research Assistant in Switzerland and at Palacký University, where he developed analytical techniques for clinical and neurological studies using mass spectrometry. His earlier roles include assisting in electrochemical method development at Lund University and clinical toxicology at Faculty Hospital Olomouc. His leadership extends to managing multimillion-CZK budgets and delivering impactful results in EU-funded research projects. Throughout his career, he has seamlessly combined academic excellence with innovation, leading to patented technologies and industrial prototypes, while mentoring young researchers and collaborating with international scientific networks.

Honors & Awards:

Dr. Václav Ranc has received several national and international honors for his scientific excellence. Notable among them is the Golden Medal at the International Invent Arena for the innovative KeyLock authentication system. He also earned the Bronze Prize from MERCK’s Young Analytical Chemists Competition and was a Finalist for the prestigious Shimadzu Prize for Young Analytical Chemists. His awards reflect consistent recognition for his groundbreaking work in analytical chemistry and applied nanotechnology. These accolades underscore his ability to translate complex research into practical applications, particularly in biosensing, authentication systems, and advanced materials. Dr. Ranc’s career is marked by impactful innovations that bridge academic research with industry needs, affirming his role as a thought leader in his field. His awarded projects and patents have contributed significantly to medical diagnostics, material sciences, and anti-counterfeiting technologies.

Research Focus:

Dr. Ranc’s research focuses on analytical chemistry, nanotechnology, and biosensing. He specializes in Raman spectroscopy (including SERS), LC/GC-MS, and the development of plasmonic and electronic nanosensors. His work bridges basic science and applied innovation, emphasizing the synthesis of nanoparticles, development of authenticity verification systems, and detection of biomarkers in clinical diagnostics. His contributions to surface-enhanced Raman spectroscopy have led to the development of patented methods and tools, including test strips and analytical systems. Dr. Ranc’s interdisciplinary approach combines analytical method development, data analysis using Python, R, and Matlab, and project management of EU-funded research. His current Horizon Europe projects focus on medical applications of nanotechnology, contributing to improved diagnostics, drug delivery systems, and authenticity verification. Through collaborations with European research institutions and industries, Dr. Ranc is pushing the boundaries of next-gen biomedical and analytical technologies.

Publication Top Notes:

  1. Magnetic 2D Transition-Metal-Based Nanomaterials in Biomedicine: Opportunities and Challenges in Cancer Therapy

  2. Highly Cytotoxic Copper(II) Mixed-Ligand Quinolinonato Complexes: Pharmacokinetic Properties and Interactions with Drug Metabolizing Cytochromes P450

  3. Graphene Oxide Nanoplatforms to Enhance Cisplatin-Based Drug Delivery in Anticancer Therapy

  4. Polymer-Based Graphene Derivatives and Microwave-Assisted Silver Nanoparticles Decoration as a Potential Antibacterial Agent

  5. New Limits for Stability of Supercapacitor Electrode Material Based on Graphene Derivative

  6. Label-free Determination of Prostate Specific Membrane Antigen in Human Whole Blood by Magnetically Assisted SERS

  7. Cyanographene and Graphene Acid: Emerging Derivatives Enabling High-Yield and Selective Functionalization of Graphene

  8. Detection of Prosthetic Joint Infection Based on Magnetically Assisted Surface Enhanced Raman Spectroscopy

  9. Functional Nanosheet Synthons by Covalent Modification of Transition-Metal Dichalcogenides

  10.  Nanoporous Nitrogen-Doped Graphene Oxide/Nickel Sulfide Composite Sheets for Hydrogen and Oxygen Evolution

Conclusion:

In conclusion, Dr. Václav Ranc is an exceptional candidate for the Best Researcher Award, demonstrating a rare synergy of academic excellence, applied innovation, and impactful leadership. His contributions to analytical chemistry and nanotechnology have advanced both scientific understanding and practical diagnostic solutions. His impressive publication record, international collaborations, patent portfolio, and success in leading multimillion-euro projects set him apart as a researcher of outstanding merit. With minor expansion into global research programs and commercialization efforts, Dr. Ranc is poised to further amplify his already significant impact. For his sustained contributions to science, his ability to lead and innovate, and his commitment to solving real-world problems through chemistry and nanotechnology, Dr. Václav Ranc is highly deserving of the Best Researcher Award.

Sunila Pradeep | Ovarian Cancer | Women Researcher Award

Published on by Cell Biologist

Dr. Sunila Pradeep | Ovarian Cancer | Women Researcher Award

Dr. Sunila Pradeep | The Medical College of Wisconsin | United States

Dr. Sunila Pradeep, Ph.D., is an accomplished Associate Professor at the Medical College of Wisconsin, with over two decades of academic and research experience in immunology, oncology, and translational medicine. Originating from India, Dr. Pradeep began her journey in microbiology before delving deep into cancer research. Her multidisciplinary work bridges basic science with clinical relevance, particularly in ovarian and uterine cancers. Having trained in globally recognized institutions like the Weizmann Institute (Israel) and MD Anderson Cancer Center (USA), she has cultivated a robust research portfolio. Her impact in biomedical sciences is well-established. Dr. Pradeep’s ongoing work on extracellular vesicles, tumor microenvironment, and therapy resistance showcases her commitment to solving real-world clinical problems. A recipient of numerous national and international honors, she is a role model for aspiring women in science, blending scientific rigor with compassionate mentorship.

Publication Profile: 

Scopus

Education:

Dr. Sunila Pradeep’s academic path began in India, where she completed her B.Sc. and M.Sc. in Microbiology at Bharathiar University, Coimbatore, Tamil Nadu. Her passion for biomedical sciences led her to pursue a Ph.D. in Immunology at the University of Calicut, Kerala, under the mentorship of Dr. Girija Kuttan, where she began her exploration into natural compounds with anti-cancer properties. Her graduate studies laid a strong foundation in experimental biology and immunomodulation. Eager to expand her research horizons globally, she pursued postdoctoral training at the Weizmann Institute of Science in Israel, and later at the prestigious MD Anderson Cancer Center, Texas, USA, where she transitioned into translational cancer research. This diverse academic journey spanning three countries has given Dr. Pradeep a unique global perspective, rigorous research training, and an innovative approach to solving complex oncological challenges.

Professional Experience:

Dr. Sunila Pradeep has more than 18 years of research experience in oncology and immunology. Her professional career began with a Postdoctoral Fellowship at the Weizmann Institute, where she explored molecular signaling in cancer progression. She then advanced to a key fellowship role at the MD Anderson Cancer Center, focusing on therapeutic resistance in ovarian cancer. Since joining the Medical College of Wisconsin as an Associate Professor, she has established herself as a leading researcher in ovarian tumor microenvironments, metastasis mechanisms, and extracellular vesicle biology. Her role extends beyond research—she is also a dedicated mentor to graduate students and postdocs, and contributes to several multidisciplinary cancer initiatives. Dr. Pradeep’s scientific rigor, grant success, and translational insights have made her a sought-after collaborator. Her efforts to bridge laboratory research with clinical application reflect her commitment to improving outcomes for women suffering from gynecologic cancers.

Awards and Honors:

Dr. Pradeep’s distinguished career has been marked by several prestigious awards. She received the Fr. Gabriel Award from the Amala Institute of Medical Sciences, Kerala, recognizing her excellence in immunology research. During her tenure at MD Anderson Cancer Center, she was honored with the Trainee Excellence Award, reflecting her high-impact work in cancer biology. Her promising contributions to ovarian cancer research earned her the Scholar-in-Training Award from the Marsha Rivkin Center Foundation for Ovarian Cancer Research—a significant achievement for emerging leaders in gynecologic oncology. These accolades underscore her strong scientific foundation, innovation, and leadership in translational oncology. Beyond individual awards, her prolific publication record and active engagement in scientific communities amplify her impact. Dr. Pradeep’s recognition across three continents emphasizes her global footprint and her consistent commitment to advancing women’s health through science.

Research Focus:

Dr. Sunila Pradeep’s research revolves around understanding tumor biology, metastasis, angiogenesis, immunomodulation, and drug resistance in gynecologic cancers, particularly ovarian and uterine cancers. She investigates the role of extracellular vesicles, tumor-derived signals, and the tumor microenvironment in driving cancer progression and therapy evasion. Her lab explores novel biomarkers and targets for overcoming VEGF resistance, improving chemotherapy response, and modulating the immune system to suppress tumor growth. Her translational work includes identifying new combination therapies (e.g., selinexor with eribulin) and examining gut microbiota’s role in estrogen signaling—connecting metabolic and hormonal networks with cancer biology. She is also involved in cutting-edge research on RNA-binding proteins, such as FXR1, and their roles in mRNA translation in cancer. With cross-disciplinary collaborations and NIH-supported studies, her focus bridges fundamental discovery with real-world clinical applications. Her ultimate goal: to make therapies more precise, personalized, and effective for women with cancer.

Publications Top Notes: 

  1. Immunomodulatory and antitumor activity of Piper longum Linn. and piperine

  2. Protective effect of Piper longum fruit ethanolic extract on radiation-induced damages in mice

  3. Expression of VEGF and VEGF receptors in tumor angiogenesis and malignancies

  4. Protective effect of Thuja occidentalis against radiation-induced toxicity in mice

  5. Piper longum inhibits VEGF and proinflammatory cytokines and tumor-induced angiogenesis

  6. Antimetastatic activity of Thuja occidentalis in a mouse model

  7. Inhibition of carcinogenesis by homeopathic drugs

  8. Effect of homeopathic medicines on transplanted tumors in mice

  9. Dynamized preparations in cell culture

  10. Phosphomimetic mutants of PEDF with enhanced antiangiogenic activity as anticancer agents

Conclusion:

Overall, Dr. Sunila Pradeep is highly qualified and a strong candidate for a Best Researcher Award in ovarian cancer research. Her prolific publication record, substantial citation impact, and focus on innovative cancer biology and treatment research provide a solid foundation for recognition. By highlighting her leadership contributions, translational impact, and broader scientific engagement, she can further strengthen her nomination. Her work clearly advances the field of ovarian cancer and serves as a model for impactful biomedical research, making her a deserving contender for such a prestigious award.

 

Tamara Braut | Cancer Cell Biology | Innovative Research Award

Published on by Cell Biologist

Prof. Dr. Tamara Braut | Cancer Cell Biology | Innovative Research Award

Prof. Dr. Tamara Braut | Faculty of Medicine, University of Rijeka/ENT Clinic, Clinical hospital centre Rijeka | Croatia

Professor Tamara Braut, MD, is a renowned Croatian otorhinolaryngologist and Full Professor at the Faculty of Medicine, University of Rijeka. She serves as the Head of the Department of Otorhinolaryngology and Head and Neck Surgery. Her clinical expertise and academic leadership have significantly contributed to advancements in the diagnosis and treatment of head and neck cancers, particularly laryngeal carcinoma. With over two decades of experience, Dr. Braut is widely recognized for her work in molecular oncology, HPV-associated head and neck tumors, and translational medicine. A frequent collaborator on interdisciplinary and international projects, she is committed to personalized medicine and innovative approaches in clinical research. Her impressive portfolio of peer-reviewed publications, including case studies, multicenter analyses, and biomarker-based diagnostics, highlights her dedication to evidence-based practice and academic excellence. Professor Braut’s academic leadership and clinical insight place her among the top contributors in her specialty within Croatia and internationally.

Publication Profile:

Google Scholar

Strengths For Award:

  • Pioneering work in head and neck oncology and molecular diagnostics

  • Significant publication record in high-impact journals

  • Collaborative multicenter research and precision medicine orientation

  • Demonstrated leadership in academic and clinical settings

  • Integration of clinical insights with research innovation

Areas for Improvement:

  • Broaden research beyond oncology to explore ENT-related AI/technology

  • Increase international collaborations and visibility at global conferences

  • Expand into clinical trials for therapeutics in HPV+ cancers

🎓 Education: 

Prof. Tamara Braut received her Doctor of Medicine (MD) degree from the University of Rijeka, Croatia, where she also completed her specialization in Otorhinolaryngology. Her academic path was distinguished by an early interest in oncology, molecular pathology, and surgical innovation. She pursued postgraduate training and research with a focus on laryngeal and head and neck cancers. Throughout her education, she was actively involved in academic research, participating in numerous national and international conferences, which sharpened her analytical and investigative skills. She later obtained her PhD with a focus on molecular markers in squamous cell carcinoma. Over the years, she has pursued continuous professional development in precision medicine, oncology biomarkers, and evidence-based surgical practices. Her academic and clinical training has made her a highly competent physician-scientist, well-versed in both patient care and experimental research.

🧑‍🔬 Experience:

Prof. Tamara Braut has over two decades of experience in clinical and academic medicine. She currently serves as the Head of the Department of Otorhinolaryngology and Head and Neck Surgery at the Faculty of Medicine, University of Rijeka. Her career spans clinical work, academic leadership, surgical practice, and scientific research. She has treated complex cases involving laryngeal and head-neck cancers and has led multidisciplinary teams in oncology care. As an educator, she has supervised medical students, residents, and PhD candidates, many of whom now hold academic and clinical positions. Dr. Braut is a prolific researcher, contributing to over 40 peer-reviewed articles, case studies, and reviews. Her leadership in multicenter studies and her role as a principal investigator in several clinical research projects highlight her competence in collaborative and innovative medical research.

🔬 Research Focus:

Prof. Braut’s research focus lies at the intersection of head and neck oncology, molecular diagnostics, and personalized medicine. She has a keen interest in biomarker discovery, especially in HPV-positive head and neck squamous cell carcinomas, and the role of EGFR signaling pathways in cancer progression. Her work includes translational research linking clinical findings with molecular data to improve prognosis, diagnosis, and treatment strategies. She has also explored the impact of hormonal therapies, gene expression markers like Ki-67 and IMP3, and novel imaging and diagnostic tools. In recent years, she has expanded her interest to gastroesophageal reflux disease and its implications in ENT disorders. Her contributions reflect a consistent commitment to advancing precision medicine, long-term patient follow-up, and multimodal treatment outcomes. She continues to integrate research into clinical practice, thereby fostering innovation and improved patient care in the otorhinolaryngology field.

📚 Publications List Top Notes:

  1. 🧬 Laryngeal SCC shows stronger Nectin-4 vs Nectin-2 expression – CIMB (2025)

  2. 🥗 GERD Management: From PPIs to Diet & Lifestyle – Gastrointest. Disord. (2025)

  3. 🔍 Advances in HPV-Positive Head & Neck Cancer Diagnostics – Biomolecules (2024)

  4. 🧪 Biomarkers in HPV+ Head and Neck SCC: Precision Medicine – Diagnostics (2024)

  5. 💉 Testosterone Therapy in Advanced Head & Neck SCC – Crit. Rev. Oncol. Hematol. (2023)

  6. 🏥 Long-Term Care in Laryngeal Cancer: Multicenter Analysis – J Pers. Med (2023)

  7. 📊 5-Year Clinical Course in Laryngeal Tumors – Acta Clin. Croatica (2022)

  8. 🧫 Renal Cell Carcinoma Metastasis to Larynx: Rare Case – Medicina Flum (2021)

  9. 🧠 Posttraumatic Vernet Syndrome without Fracture: Case Study – Medicine (2021)

  10. ⚛️ Nuclear EGFR Expression = Poor Survival in Laryngeal Ca – AIMM (2021)

Conclusion:

Prof. Tamara Braut is highly deserving of the Innovative Research Award. Her work showcases originality, clinical relevance, and scientific depth. With a robust academic and clinical foundation, she continues to push the boundaries in ENT oncology and diagnostics.

 

Dalia Saleh | Cancer Cell Biology | Innovative Research Award

Published on by Cell Biologist

Prof. Dalia Saleh | Cancer Cell Biology | Innovative Research Award

Prof. Dalia Saleh, National Research Centre, Egypt

Dr. Dalia Osama Abd El Fattah Saleh is a distinguished pharmacologist and professor at the National Research Centre, Cairo, Egypt. With a career spanning over two decades in academic and pharmaceutical research, she specializes in molecular pharmacology, experimental therapeutics, and drug development. She earned her Ph.D. and M.Sc. in Pharmacology from Cairo University, where she also completed her undergraduate pharmacy degree with honors. Dr. Saleh’s prolific contributions to science are reflected in her extensive publication record, focusing on novel therapeutic strategies against various toxicological, metabolic, and inflammatory disorders. Her collaborative efforts have led to advancements in drug signaling pathways, phytochemical pharmacology, and nanotechnology-based delivery systems. Recognized nationally for her innovation, she has received several prestigious awards. Dr. Saleh continues to shape pharmacological research through her dedication to translational science, mentorship, and participation in international seminars and training programs.

Publication Profile: 

Google Scholar

✅ Strengths for the Award:

  • Extensive Academic Background: Holds a Ph.D., M.Sc., and B.Sc. in Pharmacology from Cairo University, with a clear focus on endocrine and vascular pharmacology from early in her career.

  • Distinguished Research Record: Authored over 25+ high-impact publications in peer-reviewed journals including Scientific Reports, Toxicology Reports, Biochemistry and Cell Biology, and Environmental Science and Pollution Research.

  • Novel Scientific Contributions:

    • Explores molecular pharmacology through cutting-edge therapeutic approaches like AMPK/mTOR signaling, Nrf2/NF-κB modulation, and natural compound pharmacodynamics.

    • Studies involve both synthetic and phytochemical-based interventions, representing a hybrid and innovative research style.

  • Awards and Recognition:

    • National recognition for her research quality and productivity by the National Research Centre, with awards received in 2015 and 2020.

    • Ranked 24th in the institution for publication volume in 2014—an indicator of sustained output.

  • Global Exposure: Participated in professional training programs at King’s College London, enhancing her knowledge in clinical drug development and data management—an asset for interdisciplinary and translational research.

  • Leadership and Longevity: Promoted through all academic ranks at NRC, from Research Assistant to Professor, demonstrating not only competence but leadership and mentorship over time.

Areas for Improvement:

  • Clinical Translation: While the preclinical research is extensive, initiating clinical trials or translational studies would further strengthen the real-world applicability of her findings.

  • Global Visibility: Although trained internationally, more international speaking engagements, keynote invitations, or editorial roles could enhance global recognition.

  • Interdisciplinary Projects: Expanding collaborations across fields such as bioinformatics or biotechnology could amplify the innovation aspect of her work.

🎓 Education:

Dr. Dalia Saleh obtained all her academic degrees from Cairo University’s esteemed Faculty of Pharmacy. She was awarded her Ph.D. in Pharmacology in 2012 for her thesis examining estrogen’s vascular effects in insulin-resistant, ovariectomized rats. Earlier, she earned her M.Sc. in 2009 with research on rosiglitazone’s effects in streptozotocin-induced vascular changes. Her academic journey began with a B.Sc. in Pharmacy in 2002, graduating with distinction and honors. Her strong educational foundation laid the groundwork for her innovative and interdisciplinary research spanning molecular pharmacology, toxicology, and metabolic disorders. Through continuous professional development, including modules at King’s College London, Dr. Saleh stays aligned with global standards in pharmacological science and clinical drug development. Her educational background combines academic excellence with practical research expertise, making her well-equipped to address complex biomedical challenges.

👩‍🔬 Experience:

Dr. Dalia Saleh has built a progressive research career at Egypt’s National Research Centre, beginning as a Research Assistant in 2003. Over the years, she rose through the ranks to become a Professor in 2022. She previously held positions as Researcher (2012–2017) and Assistant Professor (2017–2022). Throughout her tenure, she has actively contributed to preclinical pharmacology research, focusing on inflammation, neuroprotection, metabolic diseases, and organ toxicity. Her interdisciplinary approach integrates pharmacodynamics, molecular signaling, and therapeutic intervention studies using both synthetic and natural compounds. She has led numerous studies that explore drug mechanisms at cellular and systemic levels, often employing rodent disease models. Dr. Saleh’s active participation in international training (e.g., at King’s College London) highlights her global engagement and commitment to continuous learning. Her career reflects not only research productivity but also leadership in collaborative scientific initiatives and mentoring of emerging researchers.

🏆 Awards & Honors:

Dr. Dalia Saleh has received multiple accolades that underscore her impact in the field of pharmacology. She was honored with the 2020 Scientific Pioneers Award and the 2015 Scientific Encouragement Award from Egypt’s National Research Centre (NRC), recognizing her outstanding research contributions. In 2014, she received institutional recognition for both her high publication output (ranked 24th NRC-wide) and for publishing in a high-impact journal (impact factor 4.067). These achievements highlight her consistent scientific productivity and influence in biomedical research. Dr. Saleh’s awards reflect a career driven by innovation, rigor, and dedication to solving pressing health issues. Her work continues to be widely cited and applied in translational pharmacology, securing her reputation as a leading figure in her discipline. She remains an inspiration to peers and students alike, with a legacy of both scientific excellence and mentorship.

🔬 Research Focus:

Dr. Dalia Saleh’s research is rooted in experimental pharmacology, with an emphasis on cell signaling pathways, drug discovery, and natural compound pharmacodynamics. She investigates molecular mechanisms underlying chronic diseases such as diabetes, hepatic and renal injury, neurodegeneration, and inflammatory disorders. A recurring theme in her work is the modulation of key signaling axes (e.g., AMPK/mTOR, NF-κB, PI3K/Akt) in mitigating organ toxicity and disease progression. Her recent studies explore the pharmacological potential of phytochemicals, drug hybrids, and nanoformulations in preclinical models. Dr. Saleh also examines gender-specific pathophysiology, as seen in her Ph.D. research on estrogen’s role in vascular dysfunction. She actively integrates biochemical, histological, and behavioral endpoints to ensure translational relevance. By bridging traditional medicine and molecular pharmacology, her work contributes to next-generation therapeutics and precision medicine. Her research has both national and global impact, frequently published in high-tier journals and cited in clinical research discussions.

📚 Publications Top Notes:

  1. 🧬 Eugenol alleviates acrylamide-induced testicular toxicity via AMPK/pAKT/mTOR signaling – Scientific Reports, 2024

  2. 💊 Trimetazidine protects against cisplatin-induced neuropathy via AMPK and Nrf2 pathways – Biochemistry and Cell Biology, 2023

  3. 🧪 Chromone-thiazolopyrimidine hybrids inhibit TNF-α, IL-6, and PGE2 – Polycyclic Aromatic Compounds, 2023

  4. 🧻 Chrysin counters cyclophosphamide-induced cystitis via STAT-3 and NF-κB inhibition – Chemico-Biological Interactions, 2023

  5. 🩺 Linagliptin and L-arginine synergize in hyperacidity via EP4 upregulation – Naunyn-Schmiedeberg’s Archives of Pharmacology, 2023

  6. 🧠 L-arginine protects against hepatic encephalopathy via anti-apoptotic mechanisms – Environmental Science and Pollution Research, 2023

  7. 🌿 Calotropis procera seed oil shows anti-inflammatory and antiparasitic activity – Arabian Journal of Chemistry, 2022

  8. 🧫 Olmesartan mitigates diabetic nephropathy through TLR4/P38-MAPK modulation – European Journal of Pharmacology, 2022

  9. 🌱 Anti-fibrotic activities of Plumbago species in liver fibrosis models – Scientific Reports, 2022

  10. 🐟 Omega-3 fatty acids protect against doxorubicin-induced liver damage – Saudi Journal of Biological Sciences, 2022

Conclusion:

Dr. Dalia O. Saleh is highly suitable for the Best Researcher Award based on her prolific scientific contributions, consistent academic progression, and commitment to impactful pharmacological research. Her strength lies in combining rigorous mechanistic studies with applied therapeutic exploration, especially in inflammation, oxidative stress, and natural product pharmacology.

wenhao chen | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. wenhao chen | Cancer Cell Biology | Best Researcher Award

Prof. wenhao chen , Zhejiang University School of Medicine Children’s Hospital National Clinical Research Center for Child Health , China

Dr. Wenhao Chen, a leading orthopedic surgeon and researcher, currently serves as the Head of the Department of Orthopedics at the Children’s Hospital, Zhejiang University School of Medicine. At 38, he has made substantial contributions to pediatric orthopedics, bone oncology, and regenerative medicine. Dr. Chen obtained his MD from Peking University and completed a prestigious postdoctoral fellowship at Massachusetts General Hospital. Known for integrating clinical expertise with biomedical research, he has authored over 17 high-impact papers, applying advanced techniques such as machine learning, gene profiling, and CRISPR screening in orthopedic studies. His work spans rare skeletal diseases, cancer metastasis, and spinal cord repair. Recognized internationally, he continues to mentor young researchers and lead translational projects. With a vision toward improving musculoskeletal health in children, his multidisciplinary approach positions him as a strong contender for the Best Researcher Award.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. Outstanding Research Productivity:
    Dr. Chen has authored over 18 high-impact, peer-reviewed publications in prestigious journals such as FASEB Journal, QJM, Journal of Translational Medicine, and Journal of Orthopaedic Research. His work spans orthopedics, oncology, regenerative medicine, and computational biology.

  2. Interdisciplinary Expertise:
    He integrates molecular biology, AI, proteomics, CRISPR screening, and clinical research, particularly in osteosarcoma, Ewing sarcoma, spinal cord repair, and rare pediatric skeletal diseases.

  3. Clinical and Academic Leadership:
    As Head of the Department of Orthopedics at a leading children’s hospital and faculty member at Zhejiang University, he demonstrates clinical leadership and research excellence.

  4. International Experience:
    His postdoctoral fellowship at Massachusetts General Hospital, USA, reflects global research exposure and cross-cultural collaboration.

  5. Translational Impact:
    Dr. Chen’s research shows a clear clinical application, such as prognosis prediction models, radiotherapy effectiveness evaluation, and gene therapy strategies for rare disorders and cancer.

🔧 Areas for Improvement:

  1. Visibility in Global Academic Forums:
    While his research is impactful, increased participation in international conferences, workshops, and symposiums could enhance visibility and networking.

  2. First-/Last-Author Publications:
    While present, a greater proportion of senior authorship could strengthen his recognition as a principal investigator or thought leader in major studies.

  3. Grant Leadership & Patent Output:
    There’s limited publicly shared information on research grants led or intellectual property (e.g., patents), which could further validate his innovation and translational output.

🎓 Education:

Dr. Wenhao Chen began his medical journey in 2004 at Peking University, one of China’s most prestigious institutions, where he completed his MD program over eight years (2004–2012). This comprehensive training gave him a robust foundation in clinical medicine and surgical practice. As part of his pursuit of global excellence, Dr. Chen was selected for a postdoctoral research position at Massachusetts General Hospital (2019–2020), affiliated with Harvard Medical School. During this international fellowship, he engaged in advanced research in orthopedics, including joint reconstruction, stem cell applications, and musculoskeletal oncology. His education reflects not only academic brilliance but also an openness to cross-border scientific collaboration. Dr. Chen’s diverse educational background enables him to merge Eastern clinical insights with Western research innovations, which he continues to apply in developing pediatric orthopedic interventions and understanding skeletal disorders on a molecular level.

💼 Experience:

With over a decade of experience in clinical orthopedics and research, Dr. Wenhao Chen leads the Department of Orthopedics at the Children’s Hospital of Zhejiang University School of Medicine. His career began in top-tier clinical hospitals in China and expanded to the U.S. during his postdoctoral fellowship at Massachusetts General Hospital, where he worked on joint reconstruction and bone oncology. In his current leadership role, he spearheads surgical treatment strategies, oversees translational research projects, and mentors medical trainees. Dr. Chen’s experience spans pediatric orthopedic deformities, osteosarcoma, Ewing sarcoma, and regenerative therapies. He’s an expert in the application of genomics, CRISPR screens, and AI in musculoskeletal disorders. His multidisciplinary projects have led to multiple grants and collaborations. Dr. Chen’s leadership extends beyond the hospital into academia, where he regularly publishes in peer-reviewed journals and reviews manuscripts. His balance of surgical excellence and innovation defines his professional experience.

🔬 Research Focus:

Dr. Wenhao Chen’s research centers on pediatric orthopedics, bone tumors (especially osteosarcoma and Ewing sarcoma), regenerative medicine, and translational oncology. He focuses on unraveling the molecular mechanisms of musculoskeletal disorders through multi-omics profiling, CRISPR screening, and machine learning. A significant part of his work addresses prognostic modeling using genomic and metabolic markers. He has also pioneered studies on gene therapy using viral vectors for spinal cord repair and the application of stem cells in congenital skeletal diseases like mucopolysaccharidosis IVA. Additionally, he investigates inflammation and autophagy signaling pathways, notably the PI3K/AKT/GSK3β axis in bone homeostasis. His translational research aims to convert biological findings into targeted clinical therapies. Dr. Chen’s work is consistently published in top-tier journals and has influenced diagnostic and therapeutic protocols in orthopedics. His blend of computational biology, clinical acumen, and lab innovation defines his impactful and forward-looking research portfolio.

📚 Publications Top Notes:

  1. 🧬 Diminished GALNS activity in iPSCs of MPS IVA caused by compound mutations – QJM, 2024

  2. 🧪 LARS as essential gene for osteosarcoma proliferation via CRISPR screening – J Transl Med, 2022

  3. 🌬️ Itraconazole mitigates lung fibrosis via SPP1/C3 signaling – J Transl Med, 2024

  4. 🔬 Chaperone-mediated autophagy protects bone formation via PI3K/AKT pathway – FASEB J, 2024

  5. 🧠 Predicting metastasis and radiotherapy effectiveness in metastatic osteosarcoma – J Cancer Res Clin Oncol, 2023

  6. 🤖 Machine learning predicts prognosis in Ewing sarcoma patients – J Orthop Res, 2021

  7. ⚡ Glycolysis-related gene score predicts osteosarcoma survival – J Orthop Res, 2022

  8. 🧫 Candidate proteins for astrocyte-to-neuron conversion via proteomics – Neural Regen Res, 2021

  9. 🦴 Surgery ± radiotherapy for malignant giant cell tumor of bone/soft tissue – J Orthop Res, 2020

  10. 🧠 NeuroD1 gene promotes glial-to-neuron conversion post-spinal cord injury – Brain Res Bull, 2017

🧾 Conclusion:

Dr. Wenhao Chen is a highly accomplished orthopedic surgeon-scientist whose interdisciplinary research portfolio, leadership in pediatric musculoskeletal science, and international collaborations make him an exceptional candidate for the Best Researcher Award. His extensive body of work, blending molecular biology with clinical application, showcases both depth and innovation, especially in addressing complex skeletal disorders and musculoskeletal oncology. With a few enhancements in international visibility and grant leadership, he is well on the path to becoming a global leader in orthopedic research.

Dengyong Zhang | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Dengyong Zhang | Cancer Cell Biology | Best Researcher Award

Prof. Dengyong Zhang , The First Affiliated Hospital of Bengbu Medical university , China

Zhang Deng Yong is a highly accomplished medical professional and researcher specializing in hepatocellular carcinoma and cholangiocarcinoma. Born in Liu’an, Anhui Province, China, in 1989, he currently works as an attending doctor at the First Affiliated Hospital of Bengbu Medical College. Dr. Zhang earned his Bachelor’s and Master’s degrees from Bengbu Medical College and is currently pursuing a Doctor’s degree at Anhui Medical University. He is also a visiting scholar at MD Anderson Cancer Center. With an extensive portfolio of research, Dr. Zhang is known for his significant contributions to the study of cancer biology, particularly in liver and biliary cancers. His commitment to medical research and patient care positions him as a key figure in the field of oncology.

Publication Profile:

Scopus

Strengths for the Award:

Dr. Zhang Deng Yong exhibits exceptional skills and commitment to the field of medical research, particularly in oncology. His advanced academic qualifications (Doctor’s degree from Anhui Medical University and a Master’s degree from Bengbu Medical College) provide a solid foundation for his innovative research. He has made significant contributions to understanding the molecular mechanisms underlying various cancers, especially hepatocellular carcinoma and cholangiocarcinoma, as evidenced by his numerous impactful publications. His collaborative work, demonstrated through his visiting scholar position at the MD Anderson Cancer Center, speaks to his ability to engage in high-caliber research environments.

Areas for Improvement:

While Dr. Zhang’s research portfolio is robust, expanding his involvement in interdisciplinary research or establishing collaborations beyond oncology could open new avenues in cancer treatment and prevention. Additionally, enhancing his focus on translational medicine could bridge the gap between laboratory research and clinical application.

Education:

Dr. Zhang Deng Yong’s academic journey began at Bengbu Medical College, where he earned his Bachelor’s degree in Medicine (2007-2012). He furthered his education with a Master’s degree in Surgery from the same institution (2012-2015). Currently, he is pursuing a Doctor’s degree at Anhui Medical University (2021-2024), specializing in oncology and cancer treatment. His dedication to academic excellence is reflected in his continued involvement in both teaching and advanced clinical research. In addition to his formal education, Dr. Zhang has participated in various international conferences and academic collaborations, further strengthening his expertise in medical research and surgery.

Experience:

Dr. Zhang has a solid background in clinical practice and research. Since 2016, he has served as an attending doctor at the First Affiliated Hospital of Bengbu Medical College, where he specializes in oncology and surgery. He also worked as a resident at Lu’an Traditional Chinese Medicine Hospital from 2015 to 2016. In 2022, Dr. Zhang had the opportunity to enhance his research experience as a visiting scholar at MD Anderson Cancer Center, a leading institution in cancer research. His clinical experience, combined with his academic training, allows him to offer patients the highest standard of care while contributing to groundbreaking cancer research. His expertise in hepatocellular carcinoma and cholangiocarcinoma has made him a sought-after expert in his field.

Awards and Honors:

Dr. Zhang Deng Yong’s commitment to research and medicine has earned him various recognitions and funding opportunities. He was awarded a Natural Science Fund of Anhui Province support from 2018 to 2020. Additionally, his work has been widely recognized in the academic community, where he has acted as a reviewer for multiple prestigious journals such as Oncology Reports, Molecular Medicine Reports, Oncology Letters, and Experimental and Therapeutic Medicine. These roles reflect his standing in the medical and scientific community. His involvement in clinical and research innovation has placed him at the forefront of oncology research, especially in the areas of hepatocellular carcinoma and cholangiocarcinoma.

Research Focus:

Dr. Zhang’s research primarily focuses on cancer biology, particularly hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). He is dedicated to understanding the molecular mechanisms behind cancer progression, immune responses, and therapeutic resistance. His work includes investigating the roles of various genetic and epigenetic factors in the development of liver and biliary cancers, as well as identifying potential biomarkers for early diagnosis and prognosis. Dr. Zhang’s research extends to exploring novel therapeutic approaches, including immunotherapy, targeted therapies, and the use of CRISPR technology. His publications also delve into the immune landscape and molecular pathways that influence cancer progression, with an emphasis on improving patient outcomes through precision medicine. His passion for cancer research and patient care continues to drive his work and innovations in the field.

Publications Top Notes:

  1. Immunosenescence and immunotherapy in elderly patients with hepatocellular carcinoma 🧬🦠

  2. USP1 promotes cholangiocarcinoma progression by deubiquitinating PARP1 to prevent its proteasomal degradation 🧬⚡

  3. CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon 🔬🧬

  4. MiR-186-5p prevents hepatocellular carcinoma progression by targeting methyltransferase-like 3 that regulates m6A-mediated stabilization of follistatin-like 5 💡🧬

  5. The COL7A1/PI3K/AKT axis regulates the progression of cholangiocarcinoma 🔬🧬

  6. Integrative analysis of bulk and single-cell transcriptomic data reveals novel insights into lipid metabolism and prognostic factors in hepatocellular carcinoma 🧬💡

  7. HSDL2 knockdown promotes the progression of cholangiocarcinoma by inhibiting ferroptosis through the P53/SLC7A11 axis ⚡🔬

  8. Application of mesohepatectomy with caudate lobectomy for the treatment of type III–IV hilar cholangiocarcinoma: a single-center retrospective study 🏥📑

  9. Prognostic model for hepatocellular carcinoma based on anoikis-related genes: immune landscape analysis and prediction of drug sensitivity 🔬💉

  10. Bile metabolites as diagnostic biomarkers for perihilar cholangiocarcinoma 🧬💡

Conclusion:

Dr. Zhang Deng Yong’s expertise in cancer research, particularly his contributions to hepatocellular carcinoma and cholangiocarcinoma, places him as a strong contender for the Research for Best Researcher Award. His dedication to advancing medical knowledge, coupled with his impressive list of publications and international collaboration, makes him an invaluable asset to the scientific community. With continued growth in clinical application, Dr. Zhang is poised for further recognition and impactful contributions to medical research.